Enabling Technologies with a Flexible Platform
Flexible Assay Technology for Studying Diverse Applications
Most Eurofins DiscoverX® cell lines and cell-based assays are based on the Enzyme Fragment Complementation Technology (EFC) technology. This patented technology provides drug discovery and development researchers the means to interrogate biomolecular reactions for advancing therapeutic drug screening and development programs. EFC is a homogeneous detection assay system that enables you to measure and rank ligand potencies, discover the MOA, perform binding and functional screens, identify novel compounds, and much more.
EFC has been used as a robust and reliable assay technology for decades in >1M programs including >250 stability and commercial release programs. Eurofins DiscoverX has developed numerous assay formats to interrogate the desired MOA of therapeutics such as PathHunter®, HitHunter®, KILR®, InCELL, and SPRINTer™. These assay formats are used from discovery through development into lot release testing and stability studies of many small molecule and biological therapeutics on the market today and within clinical trials.
Highlights
Applications
Assay Principles
Highlights
Directly Measure Relevant Target Biology with Ease
- Homogeneous Format — Add-and-read assay format without the need for washing, centrifugation, or filtration
- Robust — Enzymatically-amplified assays with large signal-to-background ratios and high precision with Z’ factors > 0.7 and lot-to-lot reproducibility
- Qualified and Validated — Extensively optimized for hundreds of targets used for screening billions of data points, and cited in thousands of peer-reviewed publications
- Scalable — Easily scalable and HTS-friendly from 96- to 3456-well microplate format
Highlights of EFC-Based Assays
| Homogeneous | Sensitive Detection | Robust | Luminescence Readout | Easy to Transfer |
|---|---|---|---|---|
|
|
|
|
|
Over 1,000 Available Functional Assays for Popular Target Classes
